590 related articles for article (PubMed ID: 12495366)
1. Background to and management of treatment-related bone loss in prostate cancer.
Berruti A; Tucci M; Terrone C; Gorzegno G; Scarpa RM; Angeli A; Dogliotti L
Drugs Aging; 2002; 19(12):899-910. PubMed ID: 12495366
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer.
Smith MR
Drugs Aging; 2003; 20(3):175-83. PubMed ID: 12578398
[TBL] [Abstract][Full Text] [Related]
3. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.
Smith MR
Oncology (Williston Park); 2004 May; 18(5 Suppl 3):21-5. PubMed ID: 15202584
[TBL] [Abstract][Full Text] [Related]
4. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.
Ross RW; Small EJ
J Urol; 2002 May; 167(5):1952-6. PubMed ID: 11956415
[TBL] [Abstract][Full Text] [Related]
5. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
Wadhwa VK; Weston R; Mistry R; Parr NJ
BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
[TBL] [Abstract][Full Text] [Related]
6. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
Israeli RS; Ryan CW; Jung LL
J Urol; 2008 Feb; 179(2):414-23. PubMed ID: 18076933
[TBL] [Abstract][Full Text] [Related]
7. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
Higano CS
Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
[TBL] [Abstract][Full Text] [Related]
8. Bone health in men receiving androgen deprivation therapy for prostate cancer.
Eastham JA
J Urol; 2007 Jan; 177(1):17-24. PubMed ID: 17161994
[TBL] [Abstract][Full Text] [Related]
9. [Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].
Kudlacek S; Puntus T
Wien Med Wochenschr; 2012 Sep; 162(17-18):380-5. PubMed ID: 22875632
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen-deprivation therapy: a systematic review and meta-analysis.
Ding H; Yang L; Du W; Teng Y; Fu SJ; Tao Y; Lu JZ; Wang ZP
Asian Pac J Cancer Prev; 2013; 14(5):3337-43. PubMed ID: 23803126
[TBL] [Abstract][Full Text] [Related]
11. Exploring the effects of luteinizing hormone-releasing hormone agonist therapy on bone health: implications in the management of prostate cancer.
Chang SS
Urology; 2003 Dec; 62(6 Suppl 1):29-35. PubMed ID: 14706506
[TBL] [Abstract][Full Text] [Related]
12. Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate.
Magno C; Anastasi G; Morabito N; Gaudio A; Maisano D; Franchina F; Galì A; Frisina N; Melloni D
Eur Urol; 2005 May; 47(5):575-80; discussion 580-1. PubMed ID: 15826746
[TBL] [Abstract][Full Text] [Related]
13. Management of bone loss in men with prostate cancer.
Higano CS
J Urol; 2003 Dec; 170(6 Pt 2):S59-63; discussion S64. PubMed ID: 14610412
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma.
Smith MR
Cancer; 2003 Feb; 97(3 Suppl):789-95. PubMed ID: 12548577
[TBL] [Abstract][Full Text] [Related]
15. Changes in bone health and skeletal-related events following implementation of a multidisciplinary consensus statement guiding surveillance and treatment of men undergoing androgen deprivation therapy for prostate cancer.
Nelson DM; Peterson AC
Aging Male; 2010 Jun; 13(2):120-3. PubMed ID: 20158389
[TBL] [Abstract][Full Text] [Related]
16. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
17. Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer.
Wadhwa VK; Weston R; Parr NJ
BJU Int; 2010 Apr; 105(8):1082-8. PubMed ID: 19912210
[TBL] [Abstract][Full Text] [Related]
18. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures.
Poon Y; Pechlivanoglou P; Alibhai SMH; Naimark D; Hoch JS; Papadimitropoulos E; Hogan ME; Krahn M
BJU Int; 2018 Jan; 121(1):17-28. PubMed ID: 28921820
[TBL] [Abstract][Full Text] [Related]
19. Osteoporosis due to androgen deprivation therapy in men with prostate cancer.
Daniell HW
Urology; 2001 Aug; 58(2 Suppl 1):101-7. PubMed ID: 11502461
[TBL] [Abstract][Full Text] [Related]
20. French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation.
Briot K; Paccou J; Beuzeboc P; Bonneterre J; Bouvard B; Confavreux CB; Cormier C; Cortet B; Hannoun-Lévi JM; Hennequin C; Javier RM; Lespessailles E; Mayeur D; Mongiat Artus P; Vieillard MH; Debiais F
Joint Bone Spine; 2019 Jan; 86(1):21-28. PubMed ID: 30287350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
